Literature DB >> 6164555

Clinical trials of sulfonated immunoglobulin preparation for intravenous administration. II. Adverse reactions.

S Matsumoto, N Kobayashi, N Gohya.   

Abstract

Mesh：

Substances：

Year:  1981        PMID： 6164555     DOI： 10.1007/BF00441919

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN： 0340-6199            Impact factor:   3.183


× No keyword cloud information.
  10 in total

1.  [On new possibilities of intravenous gamma globulin administration].

Authors:  H E SCHULTZE; G SCHWICK
Journal:  Dtsch Med Wochenschr       Date:  1962-08-24       Impact factor: 0.628

2.  The Immunological System of the Child: Part II: Immunological Deficiency States.

Authors:  C A Janeway
Journal:  Arch Dis Child       Date:  1966-08       Impact factor: 3.791

3.  Turnover of standard-gammaglobulin, pH-4-gammaglobulin and pepsin desaggregated gammaglobulin and clinical implications.

Authors:  H Koblet; S Barandun; H Diggelmann
Journal:  Vox Sang       Date:  1967-07       Impact factor: 2.144

4.  Studies with intravenous gamma globulin.

Authors:  E Merler; F S Rosen; S Salmon; J D Crain; C A Janeway
Journal:  Vox Sang       Date:  1967-07       Impact factor: 2.144

5.  The preparation of gamma-globulin for intravenous use in Paris.

Authors:  M Steinbuch; R Audran; P Amouch; C Blatrix
Journal:  Vox Sang       Date:  1967-07       Impact factor: 2.144

6.  Undegraded -globulin for intravenous therapy. A new preparation of immune serum globulin for intravenous administration.

Authors:  W Stephan; M Hainski; J H Payne; G A Ordonez; E Shanbrom
Journal:  Vox Sang       Date:  1971-05       Impact factor: 2.144

7.  Metabolism of gamma globulin fragments in normal and agammaglobulinemic persons.

Authors:  C A Janeway; E Merler; F S Rosen; S Salmon; J D Crain
Journal:  N Engl J Med       Date:  1968-04-25       Impact factor: 91.245

8.  [Elimination of complement fixation of gamma-globulin by chemical modification with beta-propiolactone].

Authors:  W Stephan
Journal:  Z Klin Chem Klin Biochem       Date:  1969-05

9.  Advisory committee on serum -globulins. Suitability for clinical use of immune serum globulin prepared from CPD plasma. A brief review.

Authors:  J T Sgouris
Journal:  Vox Sang       Date:  1971-05       Impact factor: 2.144

10.  Reconstruction of intact gamma-globulin from S-sulfonated gamma-globulin in vivo.

Authors:  Y Masuho; K Tomibe; K Matsuzawa; T Watanabe; S Ishimoto
Journal:  J Biochem       Date:  1976-06       Impact factor: 3.387
  10 in total
  6 in total

1.  Aseptic meningitis associated with high dose intravenous immunoglobulin therapy.

Authors:  J D Watson; J Gibson; D E Joshua; H Kronenberg
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-03       Impact factor: 10.154

2.  Aseptic meningitis as complication of intravenous immunoglobulin therapy for myasthenia gravis.

Authors:  Z Meiner; T Ben-Hur; Y River; A Reches
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-07       Impact factor: 10.154

3.  Aseptic meningitis: a frequent side-effect of intravenous immunoglobulin?

Authors:  R Preminger-Shapiro; M Nussinovitch; G Soen; I Varsano
Journal:  Eur J Pediatr       Date:  1995-10       Impact factor: 3.183

4.  A prospective controlled crossover trial of a new heat-treated intravenous immunoglobulin.

Authors:  S R Zuhrie; A D Webster; R Davies; A C Fay; T B Wallington
Journal:  Clin Exp Immunol       Date:  1995-01       Impact factor: 4.330

5.  1040 prophylactic infusions with an unmodified intravenous immunoglobulin product causing few side-effects in patients with antibody deficiency syndromes.

Authors:  J Björkander; C Wadsworth; L A Hanson
Journal:  Infection       Date:  1985 May-Jun       Impact factor: 3.553

Review 6.  Adverse Effects of Immunoglobulin Therapy.

Authors:  Yi Guo; Xin Tian; Xuefeng Wang; Zheng Xiao
Journal:  Front Immunol       Date:  2018-06-08       Impact factor: 7.561
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.